Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol

Summary

CLARITY (Clinical Assessment of Response in the Treatment of Depression with Daytime Sleepiness Using Solriamfetol) is a Phase 3, double-blind, placebo-controlled, multicenter randomized withdrawal trial in patients with major depressive disorder (MDD) with excessive daytime sleepiness (EDS) symptoms consisting of an open-label solriamfetol treatment period and a randomized, double-blind treatment period.

Timeline

Start

2026-02-23

Primary completion

2028-12

Completion

2028-12

Drugs

Indications